FINWIRES · TerminalLIVE
FINWIRES

Ecolab to Gain From Stronger Volumes, Margins, UBS Says

By

Ecolab (ECL) could see stronger earnings growth as pricing, higher volumes, cost savings, AI and digital tools, and better margins support results over the next several years, UBS said in a note Tuesday.

The investment firm said Ecolab's shift toward faster-growing high-tech markets could lift annual volume growth to about 4%, above its older pace of about 1% to 2%.

UBS expects adjusted earnings per share to grow at about a 17% annual rate from 2027 to 2029, helped by stronger sales and higher margins, while high-tech sales, including semiconductor water treatment and data center cooling, could grow to 12% to 14% of total sales and support better margins.

Ecolab's broader growth areas, including life sciences, pest control, digital services, and high tech, could rise to about 25% of sales, though UBS said it expects margin growth to slow in 2026 because of raw material costs, but said margins could improve again from 2027 and reach about 24% by 2029.

UBS upgraded Ecolab to buy from neutral and raised its price target to $325 from $293.

Shares of the company were up about 4.6% in Wednesday trading.

Price: $265.63, Change: $+11.40, Percent Change: +4.48%

Related Articles

Wire

Ooma Fiscal Q1 Adjusted Earnings, Revenue Rise; Shares Gain After Hours

Ooma (OOMA) reported fiscal Q1 adjusted earnings late Tuesday of $0.35 per diluted share, up from $0.20 a year earlier.Analysts polled by FactSet expected $0.32.Revenue in the three months ended April 30 rose to $81.1 million from $65 million a year earlier.Analysts surveyed by FactSet expected $79.8 million.Ooma expects fiscal Q2 adjusted EPS of $0.33 to $0.34 on revenue of $81.6 million to $82.3 million.Analysts polled by FactSet expect EPS of $0.31 on revenue of $80.2 million.The company boosted fiscal 2027 adjusted EPS guidance to $1.29 to $1.34 on revenue of $326 million to $328.5 million. Prior guidance was EPS of $1.26 to $1.31 on revenue of $321 million to $325 million.Analysts surveyed by FactSet expect EPS of $1.29 on revenue of $322.8 million.Ooma shares rose 4.8% in after-hours trading.

$OOMA
Wire

Jade Biosciences Says First Participant Dosed in First-in-Human Phase 1 Trial of JADE201

Jade Biosciences (JBIO) said late Tuesday the first participant has been dosed in a first-in-human phase 1 clinical trial of JADE201, an investigational, half-life extended, afucosylated monoclonal antibody.The first-in-human trial is a placebo-controlled study assessing single ascending doses of JADE201 in participants with rheumatoid arthritis, according to a statement.Jade said interim phase 1 data in rheumatoid arthritis anticipated in 2027 are expected to inform indication prioritization across potential autoimmune indications supported by B cell activating factor receptor biology.

$JBIO
Wire

Zscaler Fiscal Q3 Adjusted Earnings, Revenue Rise; Q4 Guidance Set

Zscaler (ZS) reported fiscal Q3 adjusted earnings late Tuesday of $1.08 per diluted share, up from $0.84 a year earlier.Analysts polled by FactSet expected $1.01.Revenue for the three months ended April 30 was $850.5 million, up from $678 million a year earlier.Analysts surveyed by FactSet expected $835.6 million.For fiscal Q4, the company expects adjusted EPS of $1.08 to $1.09 on revenue of $875 million to $878 million. Analysts expect EPS of $1.03 on revenue of $878.6 million.For the full-year fiscal 2026, the company now expects adjusted EPS of $4.10 to $4.11 on revenue of $3.329 billion to $3.332 billion. It earlier expected adjusted EPS of $3.99 to $4.02 on revenue of $3.31 billion to $3.32 billion.Analysts expect EPS of $4.01 on revenue of $3.32 billion.

$ZS